In the largest study of its kind to date, involving 427 patients from two cohorts, the performance and optimal positioning of candidate serum biomarkers of interstitial lung disease (ILD) in systemic sclerosis (SSc) was assessed. SP-D, KL-6 and CCL18 performed best as biomarkers for ILD diagnosis, lung fibrosis severity and ILD progression, respectively. A matrix model that combined baseline concentrations of SP-D and anti-topoisomerase I antibody positivity could accurately stratify patients on the basis of their risk of fibrosis, whereas a model that incorporated CCL18 levels could stratify patients with SSc-ILD on the basis of their risk of ILD progression.
References
Original article
Elhai, M. et al. Performance of candidate serum biomarkers for systemic sclerosis-interstitial lung disease. Arthritis Rheumatol. https://doi.org/10.1002/art.40815 (2019)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
McHugh, J. Lung biomarkers in SSc: prognostic or diagnostic?. Nat Rev Rheumatol 15, 126 (2019). https://doi.org/10.1038/s41584-019-0177-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-019-0177-y